Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

anti-Tenascin C, Clone: DB7, Novus Biologicals™

Mouse Monoclonal Antibody

Manufacturer:  Novus Biologicals NBP142317

Catalog No. NBP142317

Add to cart



Tenascin C Monoclonal antibody specifically detects Tenascin C in Human, Rat samples. It is validated for Western Blot, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin.


Tenascin C
PBS solution containing 1.0% w/v BSA with 0.1% Sodium Azide
150-225, Cytotactin, Glioma-associated-extracellular matrix antigen, GMEM, GP 150-225, Hexabrachion, hexabrachion (tenascin C, cytotactin), hexabrachion (tenascin), HXBcytotactin, JI, MGC167029, Myotendinous antigen, neuronectin, tenascin, tenascin C, Tenascin-C, tenascin-C isoform 14/AD1/16, TN-C, TNGP
0.05 mg
Cancer, Neuroscience
Human, Rat
Western Blot, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin)
0.1 mg/mL
Western Blot 1:100-1:2000, Immunohistochemistry 1:10-1:500, Immunocytochemistry/Immunofluorescence 1:10-1:500, Immunohistochemistry-Paraffin 1:10-1:500
The antibody reacts with the fibrinogen-like knob-domain of tenascin protein.
Protein A or G purified
Store at 4C. Do not freeze.
The antibody recognizes the Mr 250000 and 180000 human tenascin polypeptides in immunoprecipitation and in immunoblots the Mr 250000 polypeptide. The antibody reacts with the fibrinogen-like knob-domain of tenascin protein. The antibody reacts especially with human paraffin sections. Tenascins were first characterized in the early 1980's. Since then hundreds of publications on tenascin in normal tissues, pathologically reactive tissues and carcinomas have been published. However, only recently more elective studies have been done. In these studies retrospective material from pathology files has been studied as well as larger fresh material collected during several years from patients. These studies have now attempted to reveal more specific points in carcinogenesis and pathological tissue reactions. It has been demonstrated that tenascin immunoreactivity in breast carcinoma cells could be indicative of metastasis and survival. Recent studies using retrospective material showed that the expression of tenascin in invasion border of early breast cancer significantly correlates with higher risk of distant metastasis. These studies have been continued now and the preliminary results clearly suggest that expression of tenascin in invasion border of early breast cancer is significantly associated with proliferative activity and higher risk of local recurrence. This result implicates a wide application for tenascin antibodies in the breast pathology. The point is that tenascin expression may suggest situations in which even small breast carcinomas may need more intensive complementary therapy (chemotherapy etc.). Recent studies have also shown that tenascin is significantly increased in airway basement membrane of asthmatics and rapidly decreases by inhaled steroid. This result suggests that tenascin expression may be used to monitor the disease status and outcome of treatment in different types of asthma. The monoclonal antibody to tenascin (clone DB7) is suitable for immunohistochemistry with formalin-fixed and paraffin-embedded sections. The other monoclonal antibody (clone EB2) is highly sensitive in Western blotting. Monoclonal antibody (Mab) to tenascin is derived from the hybridoma produced by fusion between myeloma cells and Balb/c spleen cells. Tenascin polypeptides isolated from spent culture supernatant of human fibroblasts isolated by affinity chromatography were used as immunogen.
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit

For Research Use Only